Cidara Therapeutics Inc. (CDTX)
Cidara Therapeutics Reaches Target Enrollment of Phase 3 ANCHOR Trial Evaluating CD388 for Prevention of Seasonal Influenza in High-Risk Populations
Cidara Therapeutics Reaches Target Enrollment of Phase 3 ANCHOR Trial Evaluating CD388 for Prevention of Seasonal Influenza in High-Risk Populations
📉 **NEGATIVE** • Medium confidence analysis (67%) • Mild negative signal • Limited downside risk **Sentiment:** Negative (5%) **Content type:** General